Notably, targeting c-ABL with the clinically approved inhibitor imatinib (STI571) can sensitize resistant breast cancer cells to lapatinib, a dual tyrosine kinase inhibitor specific for HER2 and EGFR 18. This evidence concerns the gene ABL1 and breast carcinoma.